{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:26:43Z","timestamp":1783441603847,"version":"3.54.6"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Post-marketing regulatory data suggest a potential association between atorvastatin use and memory protection; however, findings from observational studies have been inconsistent and remain a subject of controversy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study aims to investigate the correlation between atorvastatin exposure and subjective memory deficits, with the objective of providing more precise safety and efficacy information for its clinical use.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We utilized two primary data sources: the National Health and Nutrition Examination Survey (NHANES) covering the years 2001 to 2018, and the Food and Drug Administration Adverse Event Reporting System (FAERS) spanning 2011 to 2018. We systematically analyzed the correlation between atorvastatin exposure and memory function using a range of statistical methods, including descriptive statistics, multivariate logistic regression, and receiver operating characteristic (ROC) curves.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the analysis of the NHANES database, multivariate logistic regression modeling, after controlling for various factors such as demographic characteristics and lifestyle, revealed a significant association between atorvastatin use and a reduced risk of memory loss (OR\u202f=\u202f0.47; 95% CI, 0.15\u20130.79; <jats:italic>p<\/jats:italic>\u202f=\u202f0.004). This suggests that atorvastatin may offer a protective effect on memory. Conversely, our analysis of the FAERS database identified 15,277 reports of adverse reactions associated with atorvastatin, of which 401 were related to psychiatric adverse events, including memory loss. This finding indicates that while atorvastatin may not generally increase the risk of memory loss, some patients may still experience these side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study integrated data from NHANES and FAERS to provide a comprehensive analysis of the relationship between atorvastatin and memory function. On one hand, the NHANES findings support the potential benefits of atorvastatin in reducing the risk of memory loss. On the other hand, the FAERS data highlight specific cognitive side effects associated with the drug. Consequently, clinicians and patients should carefully consider both the potential benefits and risks of atorvastatin, taking into account individual patient differences and implementing appropriate monitoring strategies.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1526959","type":"journal-article","created":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T05:14:57Z","timestamp":1741583697000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Correlation of atorvastatin with subjective memory deficits: a study from the NHANES and FAERS databases"],"prefix":"10.3389","volume":"16","author":[{"given":"Hao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panli","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.2174\/1570159X18666200528142429","article-title":"Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer\u2019s disease","volume":"18","author":"Khan","year":"2020","journal-title":"Curr Neuropharmacol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","article-title":"Defeating Alzheimer\u2019s disease and other dementias: a priority for European science and society","volume":"15","author":"Winblad","year":"2016","journal-title":"Lancet Neurol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","article-title":"The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"McKhann","year":"2011","journal-title":"Alzheimers Dement"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/bs.pbr.2024.06.016","article-title":"Effects of coffee on cognitive function","volume":"288","author":"Raise-Abdullahi","year":"2024","journal-title":"Prog Brain Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/gps.4980","article-title":"The effect of reminiscence therapy on cognitive functions, depression, and quality of life in Alzheimer patients: randomized controlled trial","volume":"34","author":"L\u00f6k","year":"2019","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.2174\/1871527318666190112143834","article-title":"Behavioral experimental paradigms for the evaluation of Drug\u2019s influence on cognitive functions: interpretation of associative, spatial\/nonspatial and working memory","volume":"18","author":"Zameer","year":"2019","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1185\/030079903125001668","article-title":"Statin-fibrate combination: therapy for hyperlipidemia: a review","volume":"19","author":"Wierzbicki","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"801","DOI":"10.5740\/jaoacint.18-0200","article-title":"Atorvastatin: a review of analytical methods for pharmaceutical quality control and monitoring","volume":"102","author":"Kogawa","year":"2019","journal-title":"J AOAC Int"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1126\/science.1059344","article-title":"Structural mechanism for statin inhibition of HMG-CoA reductase","volume":"292","author":"Istvan","year":"2001","journal-title":"Science (New York, NY)"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"107614","DOI":"10.1016\/j.pharmthera.2020.107614","article-title":"Statins and autoimmunity: state-of-the-art","volume":"214","author":"Dehnavi","year":"2020","journal-title":"Pharmacol Ther"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.jsps.2020.08.025","article-title":"The potential of atorvastatin for chronic lung diseases therapy","volume":"28","author":"Tulbah","year":"2020","journal-title":"Saudi Pharm J"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"S407","DOI":"10.5281\/zenodo.8319748","article-title":"Efficacy and safety of atorvastatin in major cardiovascular events: meta-analysis","volume":"61","author":"Villegas-Quintero","year":"2023","journal-title":"Rev Med Inst Mex Seguro Soc"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4587","DOI":"10.2174\/1381612825666190117114305","article-title":"The role of statins in the management of nonalcoholic fatty liver disease","volume":"24","author":"Doumas","year":"2018","journal-title":"Curr Pharm Des"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.31557\/APJCP.2022.23.3.867","article-title":"Atorvastatin inhibits viability and migration of MCF7 breast Cancer cells","volume":"23","author":"Abolghasemi","year":"2022","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref15","first-page":"1219","article-title":"Atorvastatin inhibits proliferation and promotes apoptosis of colon cancer cells via COX-2\/PGE2\/\u03b2-catenin pathway","volume":"26","author":"Cai","year":"2021","journal-title":"J BUON"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/s0002-9149(02)03270-8","article-title":"Prevention of stroke and dementia with statins: effects beyond lipid lowering","volume":"91","author":"Vaughan","year":"2003","journal-title":"Am J Cardiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00228-005-0073-z","article-title":"Effects of atorvastatin on higher functions","volume":"62","author":"Parale","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2165\/00003495-200363090-00004","article-title":"Statin treatment and progression of atherosclerotic plaque burden","volume":"63","author":"Grobbee","year":"2003","journal-title":"Drugs"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1471-2210-8-14","article-title":"Ameliorative role of atorvastatin and Pitavastatin in L-methionine induced vascular dementia in rats","volume":"8","author":"Koladiya","year":"2008","journal-title":"BMC Pharmacol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/sj.bjp.0704070","article-title":"A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid","volume":"133","author":"Stalker","year":"2001","journal-title":"Br J Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1620\/tjem.209.311","article-title":"Fluvastatin alters psychomotor performance and daily activity but not the spatial memory in rats","volume":"209","author":"Baytan","year":"2006","journal-title":"Tohoku J Exp Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"291","DOI":"10.4103\/0022-3859.90078","article-title":"An evaluation of the effect of atorvastatin on memory and psychomotor functions in hypertensive patients","volume":"57","author":"Prajapati","year":"2011","journal-title":"J Postgrad Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1592\/phco.23.15.1663.31953","article-title":"Cognitive impairment associated with atorvastatin and simvastatin","volume":"23","author":"King","year":"2003","journal-title":"Pharmacotherapy"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1592\/phco.23.7.871.32720","article-title":"Statin-associated memory loss: analysis of 60 case reports and review of the literature","volume":"23","author":"Wagstaff","year":"2003","journal-title":"Pharmacotherapy"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170, 000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet (London, England)"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/jamainternmed.2013.6184","article-title":"Statins and musculoskeletal conditions, arthropathies, and injuries","volume":"173","author":"Mansi","year":"2013","journal-title":"JAMA Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/S0140-6736(07)60716-8","article-title":"The safety of statins in clinical practice","volume":"370","author":"Armitage","year":"2007","journal-title":"Lancet (London, England)"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/j.amjcard.2006.02.030","article-title":"Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force","volume":"97","author":"McKenney","year":"2006","journal-title":"Am J Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.1177\/23247096211014050","article-title":"Severe liver injury associated with high-dose atorvastatin therapy","volume":"9","author":"Saha","year":"2021","journal-title":"J Investig Med High Impact Case Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(12)61190-8","article-title":"Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial","volume":"380","author":"Ridker","year":"2012","journal-title":"Lancet (London, England)"},{"key":"ref31","unstructured":"2009"},{"key":"ref32","unstructured":"2012"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"688","DOI":"10.7326\/0003-4819-159-10-201311190-00007","article-title":"Statins and cognitive function: a systematic review","volume":"159","author":"Richardson","year":"2013","journal-title":"Ann Intern Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/j.amjcard.2005.12.017","article-title":"An assessment of statin safety by neurologists","volume":"97","author":"Brass","year":"2006","journal-title":"Am J Cardiol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"945159","DOI":"10.3389\/fendo.2022.945159","article-title":"Association between osteoporosis or osteopenia and taking antiplatelet agents in general US population of NHANES","volume":"13","author":"Lv","year":"2022","journal-title":"Front Endocrinol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","article-title":"Open vigil--free eyeballs on AERS pharmacovigilance data","volume":"30","author":"B\u00f6hm","year":"2012","journal-title":"Nat Biotechnol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1249\/MSS.0000000000002927","article-title":"Higher 24-h Total movement activity percentile is associated with better cognitive performance in U.S. older adults","volume":"54","author":"Dooley","year":"2022","journal-title":"Med Sci Sports Exerc"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4097\/kja.21209","article-title":"Receiver operating characteristic curve: overview and practical use for clinicians","volume":"75","author":"Nahm","year":"2022","journal-title":"Korean J Anesthesiol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"109283","DOI":"10.1016\/j.yebeh.2023.109283","article-title":"Mining and analysis of adverse drug reactions associated with perampanel based on FAERS database","volume":"145","author":"Liu","year":"2023","journal-title":"Epilepsy Behav"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"13669","DOI":"10.18632\/aging.205217","article-title":"Atorvastatin mitigates memory deficits and brain monocyte infiltration in chronic hypercholesterolemia","volume":"15","author":"Gong","year":"2023","journal-title":"Aging"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.brainres.2013.03.029","article-title":"Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson\u2019s disease","volume":"1513","author":"Castro","year":"2013","journal-title":"Brain Res"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"148","DOI":"10.2174\/1386207326666230606114448","article-title":"Atorvastatin calcium ameliorates cognitive deficits through the AMPK\/Mtor pathway in rats with vascular dementia","volume":"27","author":"Li","year":"2024","journal-title":"Comb Chem High Throughput Screen"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s12031-018-1032-3","article-title":"Atorvastatin attenuates cognitive deficits and Neuroinflammation induced by A\u03b21-42 involving modulation of TLR4\/TRAF6\/NF-\u03baB pathway","volume":"64","author":"Wang","year":"2018","journal-title":"J Mol Neurosci"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3233\/JAD-2010-100639","article-title":"Changes in cognition and amyloid-\u03b2 processing with long term cholesterol reduction using atorvastatin in aged dogs","volume":"22","author":"Murphy","year":"2010","journal-title":"J Alzheimers Dis"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.18087\/cardio.2017.9.10024","article-title":"Effects of high-dose statin therapy on cognitive functions and quality of life in very high cardiovascular risk patients","volume":"17","author":"Kobalava","year":"2018","journal-title":"Kardiologiia"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1526959\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T05:15:00Z","timestamp":1741583700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1526959\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":46,"alternative-id":["10.3389\/fneur.2025.1526959"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1526959","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"article-number":"1526959"}}